BRAVECTO® spot-on for DOGS at a glance
Fast, easy, and personalised protection
High pet owner satisfaction1
Simple spot on administration
ACHIEVE YEAR-ROUND COVERAGE WITH BRAVECTO
When pet owners miss a dose, they create a risk for their pet’s protection.
Did you know, only 4.8 months of protection is provided by monthly products?
On average only 4.8 months worth of monthly ectoparasite protection is purchased annually outside of health care plans.2,3
Improve your compliance coverage with Bravecto
Long-lasting protection provides fewer opportunities for gaps in coverage with fewer doses than monthly products.2
BRAVECTO spot-on for DOGS: convenient, fast-acting, nose-to-toes protection
Break the flea lifecycle with just 1 dose
Development from egg to adult can be as fast as 14 days or as long as 140 days.4
BRAVECTO stops the life cycle in one dose and kills fleas before they can produce fertile eggs.5
Continuous use of BRAVECTO protects against flea re-infestation in pets and the household.5
More than just flea and tick protection
Fleas and ticks are vectors for many dangerous diseases.6,7
BRAVECTO spot-on for dogs can be used as a treatment strategy for the control of flea allergy dermatitis (FAD).5
BRAVECTO spot-on for dogs treats demodicosis caused by Demodex canis and sarcoptic mange (Sarcoptes scabiei var. canis) infestation.5
Long-lasting systemic flea and tick protection
Learn how BRAVECTO spot-on for Dogs outlasts monthly alternatives
Long-lasting protection with just 1 dose
One dose of BRAVECTO spot-on for dogs protects your pets against fleas and ticks for nearly 3 times longer than 1 dose of any monthly treatment.5,8,9
Provides immediate flea and tick-killing activity5
BRAVECTO spot-on for dogs kills fleas in 8 hours and ticks in 12 hours.5
Approved for puppies
BRAVECTO spot-on for dogs can be used on puppies from 8 weeks old and/or dogs weighing from 2 kg.5
Trusted by millions
Over 300 million doses of BRAVECTO products have been distributed around the world.
Single dose, 100% efficacy against Demodex canis and Sarcoptes scabiei 10-12
PET OWNERS PREFER BRAVECTO
The Bravecto range is designed to give pet owners uninterrupted and worry-free time with their pets. That’s year-round protection made easy, all backed up by the Big Flea and Tick Guarantee.
Pet owner satisfaction
in the UK and US.13
of UK pet owners prefer the convenience of BRAVECTO vs. monthly products.13
97% of UK pet owners did not purchase an alternative brand after using BRAVECTO.14
What does Bravecto spot-on offer for your dogs?
Just 1 dose of BRAVECTO spot-on for dogs protects our nations pets (and their homes) from the dangers posed by fleas and ticks continuously for 12 weeks.5
Always Bravecto®
Bravecto is the only brand to offer 1 year, 12 weeks and 1 month treatment options giving vets clinical choice to deliver year-round protection for every pet’s lifestyle with Always Bravecto®.
BRAVECTO IS HERE TO SUPPORT YOU ALL YEAR ROUND
We have tools to help you start the conversation with pet owners about why year-round protection may be necessary for their pet’s lifestyle.
Discover tools that will help you engage and educate your pet owners.
Do YOU WANT TO KNOW MORE?
Complete the form so we can contact you*
General Contact Information
“*” indicates required fields
PRESCRIBING BRAVECTO spot-on for dogs
BRAVECTO spot-on for dogs is available for dogs weighing 2 kg and more.5 The fumble-free applicator makes administration easy for pet owners. It’s straightforward and, most importantly, pet friendly. The cap does not come off to offer additional safety, leaving no small parts loose for animals or children to accidentally swallow.
FREQUENTLY ASKED QUESTIONS
The following frequently asked questions (FAQs) can help answer additional questions you may have.
Fluralaner is a potent inhibitor of arthropod nervous system function by acting antagonistically on ligand-gated chloride channels (GABA-receptor and glutamate-receptor). These are insect and acarine specific GABA-gated chloride channels (GABACI) and glutamate-gated chloride channels (GluCl). Fluralaner at expected clinical concentrations showed no activity on the mammalian nervous system GABACI receptor.15
Yes, 8-week-old puppies were treated at doses of up to 280 mg fluralaner/kg body weight BW with BRAVECTO spot-on for dogs.5 In target animal safety studies, there was no evidence of medicine-related alterations in food consumption, body weight, clinical parameters or physical examination variables or clinical pathology findings.16
Fluralaner, the active ingredient in BRAVECTO, is rapidly absorbed from the application site into the subadjacent tissues, from where it is absorbed into the vascular system. Fluralaner is mainly excreted unchanged in the faeces and to a very low extent in urine.5
Yes, in laboratory studies, fluralaner was administered to dogs and cats concurrently with other antiparasitic drugs with no adverse effects observed.17-19
Yes, it is safe to use BRAVECTO spot-on all year round. Fleas and ticks can be a year-round problem, even indoors (fleas and Rhipicephalus sanguineus). Administering BRAVECTO spot-on every 12 weeks ensures dogs will be protected from fleas and ticks throughout the year.5
A growing puppy should be dosed with a pipette containing the strength of fluralaner appropriate to the body weight at the time of treatment. The field studies conducted in the EU and the US included growing puppies, and there was no evidence of lack of efficacy. BRAVECTO showed very good and continuous efficacy throughout the 12-week interval in these puppies.
BRAVECTO has a high margin of safety. In safety studies in dogs,16 BRAVECTO (fluralaner) was tested in dogs and puppies at up to 5x the recommended dose at 8-week intervals for 3 consecutive treatments. Therefore, adverse effects beyond those reported in the prescribing information are not expected if dogs are inadvertently treated twice before the recommended re-treatment interval has elapsed.5
The onset of effect (killing effect) is 8 hours for fleas and 12 hours for ticks.5
BRAVECTO first received regulatory approval in early 2014. It is backed by many clinical studies and over 80 published papers.
REFERENCES
- Lavan RP, Armstrong R, Normile D, Zhang D, Tunceli K. Results from a U.S. dog owner survey on the treatment satisfaction and preference for fluralaner against flea and tick infestations. J Vet Sci Technol. 2017;8(3):1000438. doi:10.4172/2157-7579.1000439
- Lavan R, Armstrong R, Burgio F, Tunceli K. Duration of annual canine flea and tick protection provided by dog owners in Spain. Parasit Vectors. 2018;11:458. doi:10.1186/s13071-018-3043-x
- Analyses conducted by Animalytics on behalf of MSD Animal Health from January 2019 to December 2019 using a panel of 123 practices and purchases recorded from 11,441 dogs
- European Scientific Counsel Companion Animal Parasites. Control of ectoparasites in dogs and cats: ESCCAP Guidelines 03 Seventh edition. January 2022. Accessed November 21, 2023. https://esccap.org/uploads/docs/eiw2uedg_0720_ESCCAP_GL3_English_v18_1p.pdf
- BRAVECTO® DOG SPOT ON DATA SHEET: https://www.noahcompendium.co.uk/?id=-461528
- Taenzler J, Liebenberg J, Roepke RKA, Heckeroth AR. Prevention of transmission of Babesia canis by Dermacentor reticulatus ticks to dogs after administration of fluralaner spot-on solution. Parasite Vectors. 2016;9:234. doi:10.1186/s13071-016-1481-x
- Gopinath D, Meyer L, Smith J, Armstrong R. oral fluralaner efficacy against flea (Ctenocephalides felis) transmission of Dipylidium caninum infection to dogs. Parasite Vectors. 2018;11:557. doi:10.1186/s13071-018-3140-x
- Williams H, Young DR, Qureshi T, Zoller H, Heckeroth AR. Fluralaner, a novel isoxazoline, prevents flea (Ctenocephalides felis) reproduction in vitro and in a simulated home environment. Parasite Vectors. 2014;7:275. doi:10.1186/1756-3305-7-275
- Taenzler J, Wengenmayer C, Williams H, et al. Onset of activity of fluralaner (BRAVECTO™) against Ctenocephalides felis on dogs. Parasite Vectors. 2014;7:567. doi:10.1186/s13071-014-0567-6
- Petersen, I., et al., A European field assessment of the efficacy of fluralaner (BRAVECTO®) chewable and spot-on formulations for treatment of dogs with generalized demodicosis. Parasit Vectors, 2020. 13(1): p. 304.
- Chiummo R, Petersen I, Plehn C, Zschiesche E, Roepke R, Thomas E. Efficacy of orally administered fluralaner (BRAVECTO®) for treatment of client-owned dogs with sarcoptic mange under field conditions. Parasite Vectors. 2020;13:524. doi:10.1186/s13071-020-04395-6
- Taenzler J, Liebenberg J, Roepke RKA, Frénais R, Heckeroth AR. Efficacy of fluralaner administered orally for the treatment of naturally acquired Sarcoptes scabiei var. canis infestation in dogs. Parasite Vectors. 2016;9:392. doi:10.1186/s13071-016-1670-7
- Lavan R, Armstrong R, Lipworth K, Normile D, Newbury H. Flea and tick treatment satisfaction, preference, and adherence of dog owners in the United States, United Kingdom, and Australia who treated their dog with fluralaner. Open Vet J. 2020;10(2):135-143. doi:10.4314/ovj.v10i2.3
- Lavan R, Heaney K, Vaduvoor SR, Tunceli K. A comparative analysis of heartworm medication use patterns for dogs that also receive ectoparasiticides. Parasite Vectors. 2018;11:493. doi:10.1186/s13071-018-3076-1
- Gassel M, Wolf C, Noack S, Williams H, Ilg T. The novel isoxazoline ectoparasiticide fluralaner: selective inhibition of arthropod γ-aminobutyric acid- and L-glutamate-gated chloride channels and insecticidal/acaricidal activity. Insect Biochem Mol Biol. 2014;45:111-24. doi:10.1016/j.ibmb.2013.11.009
- Walther FM, Allan MJ, Roepke RKA, Nuernberger MC. Safety of fluralaner chewable tablets (BRAVECTO), a novel systemic antiparasitic drug, in dogs after oral administration. Parasite Vectors. 2014;7:87. doi:10.1186/1756-3305-7-87
- Animalytics report 2018
- Walther FM, Allan MJ, Roepke RK. Plasma pharmacokinetic profile of fluralaner (BRAVECTO™) and ivermectin following concurrent administration to dogs. Parasite Vectors. 2015;8. doi:10.1186/s13071-015-1123-8
- Walther FM, Allan MJ, Roepke RK, Nuernberger MC. Safety of concurrent treatment of dogs with fluralaner (BRAVECTO™) and milbemycin oxime – praziquantel. Parasite Vectors. 2014;7. doi:10.1186/s13071-014-0481-y
- Walther, F.M., P. Fisara, and R.K.A. Roepke, Safety of administration of fluralaner plus moxidectin concurrently with praziquantel in cats. Parasite Vectors, 2018. 11(1): p. 597
Bravecto® Spot-on for Cats and Bravecto® Chewable Tablets, Spot-on for Dogs and Bravecto® 150 mg/ml powder and solvent for suspension for injection for dogs contain fluralaner. POM-V.
Bravecto® Plus Spot-on for Cats contains fluralaner and moxidectin. POM-V.
Further information is available from the SPC, Datasheet or package leaflet.
Advice should be sought from the medicine prescriber. Prescription decisions are for the person issuing the prescription alone.
Use Medicines Responsibly.
MSD Animal Health UK Limited. Registered office Walton Manor, Walton, Milton Keynes MK7 7AJ, UK. Registered in England & Wales no. 946942.
